Vivos Therapeutics, Inc.
VVOS Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 27, 2026
$0.13
KIRA · Stoqly’s AI analyst, in plain words
- Vivos Therapeutics, Inc. had $17.4M of revenue in fiscal 2025, up 16.0% on the year before. Over five years, revenue changed +5.9% a year on average.
- Its operating margin was −114.1%, down 39.7 pts: of every 100 in sales, about −114 is left after running the business.
- Vivos Therapeutics, Inc. lost $21.2M in fiscal 2025.
- Free cash flow was −$17.6M in fiscal 2025, −100.9% of revenue.
- Vivos Therapeutics, Inc. has $1.1M more cash than debt.
Market cap
$2.3M
P/E
—
Revenue
$17.4M
Net income
−$21.2M
Free cash flow
−$17.6M
Operating margin
−114.1%
Vivos Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+16.0%
Yes. Sales grew 16.0% last year.
Does it make a profit?
−121.4%
No. It lost money last year.
Does profit turn into cash?
−100.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Vivos Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 15, 2026
- Legal name
- Vivos Therapeutics, Inc.
- CIK
- 0001716166
Vivos Therapeutics, Inc. · VVOS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $16.9M | $16.0M | $13.8M | $15.0M | $17.4M |
| Revenue growth | 29.2% | −5.1% | −13.9% | 8.9% | 16.0% |
| Gross margin | 74.6% | 62.5% | 59.9% | 60.0% | 60.4% |
| Operating margin | −120.7% | −156.2% | −125.3% | −74.3% | −114.1% |
| Net income | −$20.3M | −$23.8M | −$13.6M | −$11.1M | −$21.2M |
| Net margin | −120.2% | −148.8% | −98.4% | −74.1% | −121.4% |
| Diluted EPS | −$0.96 | −$25.90 | −$11.14 | −$2.22 | −$2.07 |
| Cash | |||||
| Cash from operations | −$15.7M | −$19.6M | −$11.9M | −$12.7M | −$15.3M |
| Capital expenditure | $2.4M | $0.9M | $0.8M | $0.6M | $2.3M |
| Free cash flow | −$18.1M | −$20.5M | −$12.7M | −$13.3M | −$17.6M |
| FCF margin | −107.4% | −128.0% | −92.4% | −88.2% | −100.9% |
| Share count change | 65.0% | −95.7% | 32.5% | 311.7% | 104.7% |
| Debt and strength | |||||
| Cash and short-term investments | $24.0M | $3.5M | $1.6M | $6.3M | $2.0M |
| Debt incl. finance leases | $1.3M | — | $1.2M | $1.2M | $0.9M |
| Shareholders' equity | $25.5M | $4.8M | $0.4M | $8.0M | −$1.5M |
| Current ratio | 3.6x | 0.8x | 0.3x | 1.5x | 0.2x |
| Interest coverage | −1,455.9x | — | — | — | −14.2x |
| Returns and quality | |||||
| Return on capital | −580.5% | — | — | −304.9% | — |
| Return on equity | −95.6% | −157.2% | −521.2% | −266.3% | −655.0% |
| Return on tangible equity | −90.8% | −1,439.9% | — | −236.8% | — |
| Piotroski F-score | 3 | 3 | 3 | 4 | 3 |
| Altman Z'' | −2.3 | −31.2 | −42.0 | −24.9 | −25.2 |
Insiders bought, 12 months
$1.8M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Vivos Therapeutics, Inc. · VVOS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.13 a share, the company is worth $2.3M.
Source: SEC EDGAR XBRL filings (CIK 0001716166). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.